References
- ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
- DouillardJYCunninghamDRothADIrinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trialLancet200035592091041104710744089
- de GramontAFigerASeymourMLeucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancerJ Clin Oncol200018162938294710944126
- SaltzLBCoxJVBlankeCIrinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study GroupN Engl J Med20003431390591411006366
- SinghASinghNBeheraDSharmaSUGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysisMed Oncol20173446428332164
- XuCTangXQuYUGT1A1 gene polymorphism is associated with toxicity and clinical efficacy of irinotecan-based chemotherapy in patients with advanced colorectal cancerCancer Chemother Pharmacol201678111913027220761
- InnocentiFUndeviaSDIyerLGenetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanJ Clin Oncol20042281382138815007088
- VilarEGruberSBMicrosatellite instability in colorectal cancer – the stable evidenceNat Rev Clin Oncol20107315316220142816
- SargentDJMarsoniSMongesGDefective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancerJ Clin Oncol201028203219322620498393
- LeDTUramJNWangHPD-1 blockade in tumors with mismatch-repair deficiencyN Engl J Med2015372262509252026028255
- OvermanMJMcdermottRLeachJLNivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 studyLancet Oncol20171891182119128734759
- MaJZhangYShenHAssociation between mismatch repair gene and irinotecan-based chemotherapy in metastatic colon cancerTumour Biol201536129599960926142736
- KimJEHongYSRyuMHAssociation between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancerCancer Sci201110291706171121679278
- MaGGeYGuDFunctional annotation of colorectal cancer susceptibility loci identifies MLH1 rs1800734 associated with MSI patientsGut20166571227122826911399
- TrojanJZeuzemSRandolphAFunctional analysis of hMLH1 variants and HNPCC-related mutations using a human expression systemGastroenterology2002122121121911781295
- XiaoXQGongWDWangSZPolymorphisms of mismatch repair gene hMLH1 and hMSH2 and risk of gastric cancer in a Chinese populationOncol Lett20123359159822740958
- JiricnyJThe multifaceted mismatch-repair systemNat Rev Mol Cell Biol20067533534616612326
- FujitaKKubotaYIshidaHSasakiYIrinotecan, a key chemotherapeutic drug for metastatic colorectal cancerWorld J Gastroenterol20152143122341224826604633
- SrinivasanGSidhuGSWilliamsonEASynthetic lethality in malignant pleural mesothelioma with PARP1 inhibitionCancer Chemother Pharmacol201780486186728756516
- Heerma van VossMRBrilliantJDVesunaFCombination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancerMed Oncol20173433328138868
- TanikawaCKamataniYTakahashiAGWAS identifies two novel colorectal cancer loci at 16q24.1 and 20q13.12Carcinogenesis201839565266029471430
- LiuNQTer HuurneMNguyenLNThe non-coding variant rs1800734 enhances DCLK3 expression through long-range interaction and promotes colorectal cancer progressionNat Commun201781441828195176
- PaolicchiEVivaldiCde GregorioVTopoisomerase 1 promoter variants and benefit from irinotecan in metastatic colorectal cancer patientsOncology201691528328827577551
- TeftWAWelchSLenehanJOATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapyBr J Cancer2015112585786525611302